Clinical Trial Update: Doxorubicin and Bortezomib in Treating Patients With Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of doxorubicin and bortezomib for hepatocellular carcinoma has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bortezomib (bortezomib)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-10-30